http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012088311-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e3bb994c4ec5ddd711d539ee1a34e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7fd38ff393036b78f4fa402ddeeae2d |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2009-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_208f7c2d039a1d0bdba23d3ca68faba9 |
publicationDate | 2012-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2012088311-A1 |
titleOfInvention | Immuno-Detection of a Cancerous State in a Subject |
abstract | The present invention is based on the finding that antibodies raised against a fragment of PAR1-released peptide may be used to detect in a bodily fluid sample from a subject a marker associated with cancer state, if said subject has cancer. Thus, the present invention provides the methods and packages for conducting one or more of the following: determining a cancerous state in a subject, the method comprises determining binding of an antibody raised against a protease-activated receptor 1 (PAR1) released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject, wherein binding of said antibody to said marker being indicative of a cancerous state; determining severity of a cancerous state in a subject comprising determining level of binding of an antibody raised against PAR1 released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject, and comparing the level of binding with the level of prior determined standards that correlate level of antibody binding to PAR1 released peptide with severity of cancerous state; and determining the effectiveness of a therapeutic treatment of a subject with an anti-cancer agent to the subject comprising determining the level of binding of an antibody raised against PAR1 released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject in two or more successive time points, one or more time points are during the therapeutic treatment, wherein a difference in the level being indicative of effectiveness of therapeutic treatment. |
priorityDate | 2008-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 148.